# OnCo record empower-cervical-1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/empower-cervical-1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "empower-cervical-1", "NCT03257267" ;
  schema:name "EMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9"@en ;
  schema:description "The first immunotherapy to extend life in recurrent cervical cancer, approved in Europe but declined by the FDA."@en ;
  schema:url <https://onco.cc/trials/empower-cervical-1/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03257267>, <https://www.nejm.org/doi/full/10.1056/NEJMoa2112187> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2017-09-05" ;
  onco:cancers <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/cemiplimab/> ;
  onco:companies <https://onco.cc/companies/regeneron/>, <https://onco.cc/companies/sanofi/> .